AU2018273963B2 - Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells - Google Patents

Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells Download PDF

Info

Publication number
AU2018273963B2
AU2018273963B2 AU2018273963A AU2018273963A AU2018273963B2 AU 2018273963 B2 AU2018273963 B2 AU 2018273963B2 AU 2018273963 A AU2018273963 A AU 2018273963A AU 2018273963 A AU2018273963 A AU 2018273963A AU 2018273963 B2 AU2018273963 B2 AU 2018273963B2
Authority
AU
Australia
Prior art keywords
cell
virus
engineered
cells
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018273963A
Other languages
English (en)
Other versions
AU2018273963A1 (en
Inventor
Alicja COPIK
Griff PARKS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Central Florida Research Foundation Inc
Original Assignee
University of Central Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Central Florida Research Foundation Inc filed Critical University of Central Florida Research Foundation Inc
Publication of AU2018273963A1 publication Critical patent/AU2018273963A1/en
Application granted granted Critical
Publication of AU2018273963B2 publication Critical patent/AU2018273963B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18732—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18745—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018273963A 2017-05-25 2018-05-25 Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells Active AU2018273963B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762511010P 2017-05-25 2017-05-25
US62/511,010 2017-05-25
PCT/US2018/034655 WO2018218151A1 (en) 2017-05-25 2018-05-25 Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells

Publications (2)

Publication Number Publication Date
AU2018273963A1 AU2018273963A1 (en) 2020-01-23
AU2018273963B2 true AU2018273963B2 (en) 2023-07-20

Family

ID=64397136

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018273963A Active AU2018273963B2 (en) 2017-05-25 2018-05-25 Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells

Country Status (10)

Country Link
US (2) US11684637B2 (https=)
EP (1) EP3630144A4 (https=)
JP (2) JP7522426B2 (https=)
KR (2) KR102700175B1 (https=)
CN (1) CN110891584B (https=)
AU (1) AU2018273963B2 (https=)
BR (1) BR112019024656A2 (https=)
CA (1) CA3064897A1 (https=)
IL (1) IL270876B2 (https=)
WO (1) WO2018218151A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
WO2020154640A1 (en) * 2019-01-24 2020-07-30 University Of Central Florida Research Foundation, Inc. Compositions and methods for stimulating natural killer cells
US20230330140A1 (en) * 2019-11-25 2023-10-19 Ansun Biopharma, Inc. Immune cell delivery of sialidase cancer cells, immune cells and the tumor microenvironment
CN111676245B (zh) * 2020-06-24 2022-09-13 武汉波睿达生物科技有限公司 一种含有HSV-1型溶瘤病毒的NFAT-Cre-CAR-T细胞及其应用
KR20230048046A (ko) * 2020-08-12 2023-04-10 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 감마 델타 t 세포를 자극하기 위한 방법 및 조성물
CN112852757A (zh) * 2021-02-01 2021-05-28 南京大学 一种制备新型溶瘤病毒EM/VSV-G Ad5sPVRCD137L的方法
CA3215085A1 (en) * 2021-04-08 2022-10-13 Immvira Biopharmaceuticals Co., Limited Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen
CN115678854A (zh) * 2021-07-29 2023-02-03 上海中医药大学 一种基因工程细胞及其制备方法和应用
CN116875547A (zh) * 2023-09-04 2023-10-13 山东德升细胞治疗工程技术有限公司 一种利用细胞外泌体激活nk细胞的体外扩增培养方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090214590A1 (en) * 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
US20110318355A1 (en) * 2008-11-21 2011-12-29 Centre National De La Recherche Scientifique Mutant proteins of the f protein of piv-5 and piv-2
US20140134162A1 (en) * 2006-12-08 2014-05-15 Macrogenics, Inc. Methods for the Treatment of Disease Using Immunoglobulins Having Fc Regions with Altered Affinities for FcgammaRactivating and FcgammaRinhibiting
US20170007685A1 (en) * 2013-11-05 2017-01-12 The Board Of Regents Of The University Of Texas System TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES
US20170056458A1 (en) * 2015-04-30 2017-03-02 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein or active fragment
US20170067080A1 (en) * 2012-01-24 2017-03-09 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (https=) 1968-10-17 1970-08-24
US20020187543A1 (en) * 2001-04-05 2002-12-12 Curiel David T. Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins
US20080299137A1 (en) 2005-10-28 2008-12-04 Novo Nordisk A/S Fusion Proteins That Bind Effector Lymphocytes And Target Cells
WO2008067305A2 (en) 2006-11-28 2008-06-05 Giic Research Development Corporation Polypeptides comprising intracytoplasmic death domain and nkg2d ligand domain
US20100178684A1 (en) 2006-12-21 2010-07-15 Woo Savio L C Transgenic oncolytic viruses and uses thereof
AU2009332883B2 (en) 2008-12-22 2015-05-21 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
US9592287B2 (en) * 2009-10-09 2017-03-14 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
LT3578201T (lt) * 2012-06-28 2023-05-25 University Of Central Florida Research Foundation Incorporated Nk ląstelių metodai ir kompozicijos
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2014041119A1 (en) * 2012-09-14 2014-03-20 Deutsches Krebsforschungszentrum Oncolytic viruses expressing immuno-nucleases
EP2968525A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
US10238700B2 (en) * 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
JP2017530114A (ja) 2014-09-26 2017-10-12 バヴァリアン・ノルディック・アクティーゼルスカブ フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物
HK1245080A1 (zh) * 2014-10-27 2018-08-24 University Of Central Florida Research Foundation, Inc. 自然杀伤细胞的方法和组合物
JP6797803B2 (ja) * 2014-12-31 2020-12-09 セルジーン コーポレイション ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090214590A1 (en) * 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
US20140134162A1 (en) * 2006-12-08 2014-05-15 Macrogenics, Inc. Methods for the Treatment of Disease Using Immunoglobulins Having Fc Regions with Altered Affinities for FcgammaRactivating and FcgammaRinhibiting
US20110318355A1 (en) * 2008-11-21 2011-12-29 Centre National De La Recherche Scientifique Mutant proteins of the f protein of piv-5 and piv-2
US20170067080A1 (en) * 2012-01-24 2017-03-09 University Of Georgia Research Foundation, Inc. Parainfluenza virus 5 based vaccines
US20170007685A1 (en) * 2013-11-05 2017-01-12 The Board Of Regents Of The University Of Texas System TUMORS EXPRESSING IgG1 Fc INDUCE ROBUST CD8 T CELL RESPONSES
US20170056458A1 (en) * 2015-04-30 2017-03-02 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein or active fragment

Also Published As

Publication number Publication date
EP3630144A4 (en) 2021-03-31
US20240000842A1 (en) 2024-01-04
AU2018273963A1 (en) 2020-01-23
KR102700175B1 (ko) 2024-08-30
US11684637B2 (en) 2023-06-27
KR20240132124A (ko) 2024-09-02
KR20200010405A (ko) 2020-01-30
BR112019024656A2 (pt) 2020-06-09
IL270876A (en) 2020-01-30
IL270876B2 (en) 2024-06-01
IL270876B1 (en) 2024-02-01
JP2020521447A (ja) 2020-07-27
EP3630144A1 (en) 2020-04-08
CN110891584A (zh) 2020-03-17
US12312393B2 (en) 2025-05-27
JP7522426B2 (ja) 2024-07-25
WO2018218151A1 (en) 2018-11-29
US20210145876A1 (en) 2021-05-20
JP2024133640A (ja) 2024-10-02
CA3064897A1 (en) 2018-11-29
CN110891584B (zh) 2024-02-13

Similar Documents

Publication Publication Date Title
US12312393B2 (en) Oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
US11299549B2 (en) Humanized BCMA antibody and BCMA-CAR-T cells
CN105611943B (zh) 能结合CD32B和CD79b的双特异性单价Fc双抗体及其用途
US9428574B2 (en) Polypeptides and uses thereof for treatment of autoimmune disorders and infection
JP7683932B2 (ja) ナチュラルキラー細胞を刺激するための組成物及び方法
WO2018118494A2 (en) Use of car-modified human natural killer cells to treat cancer
CN113045657B (zh) 一种人源化抗人bcma单克隆抗体及其car-t细胞
JP2023539870A (ja) グリア芽細胞腫を処置するための方法および組成物
US12528873B2 (en) Humanized BCMA antibody and BCMA-CAR-T cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)